Evidence map›Paper›PMID 41429902›Full record

ArticleScientific reports2025

Pharmacodynamics of direct oral anticoagulants associated with post-endoscopic delayed mucosal resection bleeding of colorectal neoplasms.

Masaki Murata, Mitsushige Sugimoto, Satoshi Ueshima, Yasuaki Nagami, Masaki Ominami, Yohei Furumoto, Tatsuya Mikami, Manabu Sawaya, Naohisa Yoshida, Ken Inoue and 17 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Masaki MurataDepartment of Gastroenterology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Mitsushige SugimotoDivision of Genome-Wide Infectious Diseases, Research Center for GLOBAL and LOCAL Infectious Disease, Oita University, Oita, Japan. sugimo@oita-u.ac.jp.
Satoshi UeshimaCollege of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan.
Yasuaki NagamiDepartment of Gastroenterology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Masaki OminamiDepartment of Gastroenterology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Yohei FurumotoDepartment of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
Tatsuya MikamiDivision of Endoscopy, Hirosaki University Hospital, Aomori, Japan.
Manabu SawayaDepartment of Gastroenterology, Graduate School of Medicine, Hirosaki University, Aomori, Japan.
Naohisa YoshidaDepartment of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Ken InoueDepartment of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yasuhiko MaruyamaDepartment of Gastroenterology, Fujieda Municipal General Hospital, Shizuoka, Japan.
Tomohiro TeraiDepartment of Gastroenterology, Fujieda Municipal General Hospital, Shizuoka, Japan.
Shigetsugu TsujiDepartment of Gastroenterology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan.
Takeshi YamamuraDepartment of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Aichi, Japan.
Takanori YamadaDepartment of Gastroenterology, Iwata City Hospital, Shizuoka, Japan.
Yoji TakeuchiDepartment of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.
Nobuaki YagiDepartment of Gastroenterology, Asahi University Hospital, Gifu, Japan.
Satoshi OsawaDepartment of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.
Yashiro YoshizawaDepartment of Gastroenterology, Seirei Hamamatsu General Hospital, Shizuoka, Japan.
Shunichiro OriharaDepartment of Health Data Science, Tokyo Medical University, Tokyo, Japan.
Shin'ichi MiyamotoDepartment of Gastroenterology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Sayana MatsudaCollege of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan.
Daiki HiraDepartment of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
Tomohiro TeradaDepartment of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
Toshiya KatsuraCollege of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan.
Mitsuhiro FujishiroDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Takashi KawaiCenter for Health Surveillance & Preventive Medicine, Tokyo Medical University Hospital, Tokyo, Japan.

Funding

a Grant-in-Aid from Scientific Research (C) 21K0794the JFE ( Japanese Foundation for Research and Promotion of Endoscopy) grant N/A
6 · The paper itself

Abstract

Anticoagulant effects of direct oral anticoagulants (DOACs) are influenced by their plasma levels and anti-factor Xa (FXa) activity. Delayed bleeding is a major adverse event associated with endoscopic mucosal resection (EMR) of colorectal neoplasms. However, the association between post-EMR bleeding and pharmacodynamics in patients taking DOAC remains unknown. This study investigated the association between pharmacological risk factors and delayed bleeding in patients receiving DOAC. This multicenter prospective trial in Japan evaluated the incidence of post-EMR delayed bleeding in DOAC users between April 2018 and May 2022 and determined the association of post-EMR delayed bleeding with plasma levels and FXa activity. The incidence of post-EMR delayed bleeding was 10.5% (95% confidence interval [CI]: 5.3%-18.0%). There were large individual differences in plasma levels and FXa activity for each DOAC. At the trough and Tmax, plasma DOAC levels and plasma level/dose ratios were significantly correlated with FXa activity. Multivariate analysis showed that high anticoagulant ability was a risk factor for post-EMR delayed bleeding (adjusted OR, 12.211; 95% CI: 1.081-137.922, p = 0.043). DOAC users with high anticoagulant activity may be at higher risk of post-EMR delayed bleeding from colorectal neoplasms.

Indexed as

AnticoagulantsColorectal NeoplasmsEndoscopic Mucosal ResectionFactor Xa InhibitorsGastrointestinal HemorrhagePostoperative HemorrhageAdministration, OralAgedAged, 80 and overFemaleHumansMaleMiddle AgedProspective StudiesRisk FactorsAnticoagulantsFactor Xa InhibitorsBleedingDirect oral anticoagulantEndoscopic mucosal resectionPharmacokineticsPolymorphism

Identifiers

PMID41429902
PMCPMC12749976

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.